Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29276197 | 0.89 | LPL (0.35) | LPLLIPGEGFR | |
| SCHEMBL31042939 | 0.88 | LPL (0.34) | LPLLIPGEGFR | |
| SCHEMBL22655066 | 0.88 | LPL (0.34) | LPLLIPGEGFR | |
| SCHEMBL29508571 | 0.88 | LPL (0.34) | LPLLIPGEGFR | |
| SCHEMBL26132427 | 0.85 | EGFR (0.39) | LPLLIPGEGFR | |
| SCHEMBL25418201 | 0.83 | LPL (0.46) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL327717 | 0.82 | LPL (0.40) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL443424 | 0.80 | LPL (0.39) | LPLLIPGEGFRP2RX7MAPK1 | |
| SCHEMBL10269418 | 0.80 | LPL (0.39) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL13429482 | 0.80 | LPL (0.39) | LPLLIPGP2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246018-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | WO | disclosed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | LPL 1703/4885LIPG 2039/4885EGFR 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.